AASK-CO

AASK-CO

• 批准号: 7607807
• 负责人: Otelio S Randall
• 金额: $ 12.32万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607807
• 关键词: Address; African American; Antihypertensive Agents; Cardiovascular Diseases; Caring; Cessation of life; Clinical Trials; Cohort Studies; Collection; Computer Retrieval of Information on Scientific Projects Database; Creatinine; DNA; Data; Disease Progression; End stage renal failure; Enrollment; Exposure to; Funding; Genetic; Grant; Hypertension; Institution; Kidney Diseases; Lead; Observational Study; Outcome; Participant; Pharmaceutical Preparations; Physiological; Prevention strategy; Process; Renal function; Research; Research Personnel; Resources; Risk Factors; Serum; Socioeconomic Factors; Source; United States National Institutes of Health; Universities; Visit; blood pressure regulation; cohort; hypertension treatment; prevent; prospective

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK Clinical trial. Howard University will enroll 29 in the AASK Cohort Study. Additionally, those AASK participants who reached ESRD will be invited to attend one visit for collection of DNA. Exposures to be collected twice/year including environmental, genetic, physiologic and socioeconomic factors. The primary outcome will be defined by the doubling of serum creatinine, progression to ESRD or death. Appropriate antihypertensive treatment will be provided to participants who do not have ESRD. In this fashion, the Cohort will directly control two of the major "known" determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medications) and will, therefore, address its research objectives in the setting of recommended hypertensive care. 4-6 contacts for BP control will take place per year for each participant. The duration of followup in the Cohort Study will be 5 years. The AASK Cohort Study will provide data that enhances our understanding of the processes that determine progression of renal disease. Furthermore, data from this study might ultimately lead to new prevention strategies that delay or prevent the onset of ESRD. The primary objective is to prospectively determine the long-term course of kidney function and risk factors for kidney disease progression in African Americans with hypertension-related kidney disease who receive recommended antihypertension therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors in the setting of hypertension-related kidney disease.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 AASK队列研究是一项前瞻性，观察性研究，是AASK临床试验的扩展。霍华德大学将招募29名AASK队列研究。 此外，将邀请那些到达ESRD的AASK参与者参加一次访问DNA的访问。 每年两次收集的暴露，包括环境，遗传，生理和社会经济因素。 主要结果将通过血清肌酐，进展到ESRD或死亡的一倍来定义。将为没有ESRD的参与者提供适当的降压治疗。 以这种方式，该队列将直接控制肾脏疾病进展的两个主要“已知”决定因素（高血压治疗和肾脏保护，降压药的使用），因此，将在推荐的高血压护理中解决其研究目标。 每位参与者每年将进行4-6个BP控制的联系人。 在队列研究中的随访时间为5年。 AASK队列研究将提供数据，以增强我们对决定肾脏疾病进展的过程的理解。 此外，这项研究的数据最终可能导致新的预防策略延迟或阻止ESRD的发作。 主要目的是前瞻性确定肾脏功能的长期过程和与高血压相关的肾脏疾病的非裔美国人的肾脏疾病进展的长期过程，这些肾脏疾病接受了建议的抗高血压疗法。 第二个目标是确定心血管疾病的发生，并在与高血压相关的肾脏疾病的情况下评估其危险因素。